Constitutive expression of a dominant-negative TGF-β type II receptor in the posterior left atrium leads to beneficial remodeling of atrial fibrillation substrate

Circulation Research

Volumn 119, Issue 1, 2016, Pages 69-82

  Kunamalla, Aaron ^a   Ng, Jason ^a   Parini, Vamsi ^a   Yoo, Shin ^a   Mcgee, Kate A ^a   Tomson, Todd T ^a   Gordon, David ^a   Thorp, Edward B ^a   Lomasney, Jon ^a   Zhang, Qiang ^a   Shah, Sanjiv ^a   Browne, Suzanne ^a   Knight, Bradley P ^a   Passman, Rod ^a   Goldberger, Jeffrey J ^a   Aistrup, Gary ^a   Arora, Rishi ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

atrial fibrillation; electroporation; fibrosis; gene therapy; heart failure

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN SERINE THREONINE KINASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ANIMAL MODEL; ARTICLE; ATRIAL FIBRILLATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROGRAPHY; ELECTROPORATION; ESCHERICHIA COLI; FIBROBLAST; FIBROSING ALVEOLITIS; FIBROSIS; GENE EXPRESSION; HEART ATRIUM CONDUCTION; HEART LEFT ATRIUM; HEART MUSCLE REFRACTORY PERIOD; IMMUNOFLUORESCENCE; INFLAMMATION; NONHUMAN; NONVIRAL GENE THERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING; 3T3 CELL LINE; ADMINISTRATION AND DOSAGE; ANIMAL; DOG; GENE THERAPY; GENE VECTOR; GENETICS; HEART ATRIUM; HEART ATRIUM FUNCTION; METABOLISM; MOUSE; PATHOLOGY;

3T3 CELLS; ANIMALS; ATRIAL FIBRILLATION; ATRIAL FUNCTION; DOGS; FIBROSIS; GENETIC THERAPY; GENETIC VECTORS; HEART ATRIA; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMAD PROTEINS;

EID: 84970002355     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.307878     Document Type: Article

References (71)

1. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA, Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994 271 840 844. doi: 10.1001/jama.1994.03510350050036
2. January CT, Wann LS, Alpert JS, ACC/AHA Task Force Members 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014 130 2071 2104. doi: 10.1161/CIR.0000000000000040
3. Heijman J, Voigt N, Nattel S, Dobrev D, Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res 2014 114 1483 1499. doi: 10.1161/CIRCRESAHA.114.302226
4. Schotten U, Verheule S, Kirchhof P, Goette A, Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev 2011 91 265 325. doi: 10.1152/physrev.00031.2009
5. Li D, Fareh S, Leung TK, Nattel S, Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999 100 87 95. doi: 10.1161/01.CIR.100.1.87
6. Khan R, Examining potential therapies targeting myocardial fibrosis through the inhibition of transforming growth factor-beta 1. Cardiology 2007 108 368 380. doi: 10.1159/000099111
7. Li Y, Jian Z, Yang ZY, Chen L, Wang XF, Ma RY, Xiao YB, Increased expression of connective tissue growth factor and transforming growth factor-beta-1 in atrial myocardium of patients with chronic atrial fibrillation. Cardiology 2013 124 233 240. doi: 10.1159/000347126
8. Rahmutula D, Marcus GM, Wilson EE, Ding CH, Xiao Y, Paquet AC, Barbeau R, Barczak AJ, Erle DJ, Olgin JE, Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1. Cardiovasc Res 2013 99 769 779. doi: 10.1093/cvr/cvt074
9. Hanna N, Cardin S, Leung TK, Nattel S, Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004 63 236 244. doi: 10.1016/j.cardiores.2004.03.026
10. Khan R, Sheppard R, Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006 118 10 24. doi: 10.1111/j.1365-2567.2006.02336.x
11. Verheule S, Sato T, Everett T IV, Engle SK, Otten D, Rubart-von Der Lohe M, Nakajima HO, Nakajima H, Field LJ, Olgin JE, Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004 94 1458 1465. doi: 10.1161/01.RES.0000129579.59664.9d
12. Yeh YH, Kuo CT, Chang GJ, Qi XY, Nattel S, Chen WJ, Nicotinamide adenine dinucleotide phosphate oxidase 4 mediates the differential responsiveness of atrial versus ventricular fibroblasts to transforming growth factor-β. Circ Arrhythm Electrophysiol 2013 6 790 798. doi: 10.1161/CIRCEP.113.000338
13. Lamirault G, Gaborit N, Le Meur N, Chevalier C, Lande G, Demolombe S, Escande D, Nattel S, Léger JJ, Steenman M, Gene expression profile associated with chronic atrial fibrillation and underlying valvular heart disease in man. J Mol Cell Cardiol 2006 40 173 184. doi: 10.1016/j.yjmcc.2005.09.004
14. Nakajima H, Nakajima HO, Salcher O, Dittiè AS, Dembowsky K, Jing S, Field LJ, Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. Circ Res 2000 86 571 579. doi: 10.1161/01.RES.86.5.571
15. Aistrup GL, Cokic I, Ng J, Gordon D, Koduri H, Browne S, Arapi D, Segon Y, Goldstein J, Angulo A, Wasserstrom JA, Goldberger JJ, Kadish AH, Arora R, Targeted nonviral gene-based inhibition of Gα(i/o)-mediated vagal signaling in the posterior left atrium decreases vagal-induced atrial fibrillation. Heart Rhythm 2011 8 1722 1729. doi: 10.1016/j.hrthm.2011.06.018
16. Amit G, Kikuchi K, Greener ID, Yang L, Novack V, Donahue JK, Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation 2010 121 2263 2270. doi: 10.1161/CIRCULATIONAHA.109.911156
17. Bikou O, Thomas D, Trappe K, Lugenbiel P, Kelemen K, Koch M, Soucek R, Voss F, Becker R, Katus HA, Bauer A, Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res 2011 92 218 225. doi: 10.1093/cvr/cvr209
18. Igarashi T, Finet JE, Takeuchi A, Fujino Y, Strom M, Greener ID, Rosenbaum DS, Donahue JK, Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation 2012 125 216 225. doi: 10.1161/CIRCULATIONAHA.111.053272
19. Koduri H, Ng J, Cokic I, Aistrup GL, Gordon D, Wasserstrom JA, Kadish AH, Lee R, Passman R, Knight BP, Goldberger JJ, Arora R, Contribution of fibrosis and the autonomic nervous system to atrial fibrillation electrograms in heart failure. Circ Arrhythm Electrophysiol 2012 5 640 649. doi: 10.1161/CIRCEP.111.970095
20. Ng J, Villuendas R, Cokic I, Schliamser JE, Gordon D, Koduri H, Benefield B, Simon J, Murthy SN, Lomasney JW, Wasserstrom JA, Goldberger JJ, Aistrup GL, Arora R, Autonomic remodeling in the left atrium and pulmonary veins in heart failure: creation of a dynamic substrate for atrial fibrillation. Circ Arrhythm Electrophysiol 2011 4 388 396. doi: 10.1161/CIRCEP.110.959650
21. Ng J, Borodyanskiy AI, Chang ET, Villuendas R, Dibs S, Kadish AH, Goldberger JJ, Measuring the complexity of atrial fibrillation electrograms. J Cardiovasc Electrophysiol 2010 21 649 655. doi: 10.1111/j.1540-8167.2009.01695.x
22. Koller ML, Riccio ML, Gilmour RF Jr, Dynamic restitution of action potential duration during electrical alternans and ventricular fibrillation. Am J Physiol 1998 275 H1635 H1642
23. Aistrup GL, Villuendas R, Ng J, Gilchrist A, Lynch TW, Gordon D, Cokic I, Mottl S, Zhou R, Dean DA, Wasserstrom JA, Goldberger JJ, Kadish AH, Arora R, Targeted G-protein inhibition as a novel approach to decrease vagal atrial fibrillation by selective parasympathetic attenuation. Cardiovasc Res 2009 83 481 492. doi: 10.1093/cvr/cvp148
24. Kanzler S, Meyer E, Lohse AW, Schirmacher P, Henninger J, Galle PR, Blessing M, Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis. Oncogene 2001 20 5015 5024. doi: 10.1038/sj.onc.1204544
25. Marquez-Aguirre A, Sandoval-Rodriguez A, Gonzalez-Cuevas J, Bueno-Topete M, Navarro-Partida J, Arellano-Olivera I, Lucano-Landeros S, Armendariz-Borunda J, Adenoviral delivery of dominant-negative transforming growth factor beta type II receptor up-regulates transcriptional repressor SKI-like oncogene, decreases matrix metalloproteinase 2 in hepatic stellate cell and prevents liver fibrosis in rats. J Gene Med 2009 11 207 219. doi: 10.1002/jgm.1303
26. Tae HJ, Petrashevskaya N, Marshall S, Krawczyk M, Talan M, Cardiac remodeling in the mouse model of Marfan syndrome develops into two distinctive phenotypes. Am J Physiol Heart Circ Physiol 2016 310 H290 H299. doi: 10.1152/ajpheart.00354.2015
27. Pan Z, Zhao W, Zhang X, Wang B, Wang J, Sun X, Liu X, Feng S, Yang B, Lu Y, Scutellarin alleviates interstitial fibrosis and cardiac dysfunction of infarct rats by inhibiting TGFβ1 expression and activation of p38-MAPK and ERK1/2. Br J Pharmacol 2011 162 688 700. doi: 10.1111/j.1476-5381.2010.01070.x
28. Bao MW, Zhang XJ, Li L, Cai Z, Liu X, Wan N, Hu G, Wan F, Zhang R, Zhu X, Xia H, Li H, Cardioprotective role of growth/differentiation factor 1 in post-infarction left ventricular remodelling and dysfunction. J Pathol 2015 236 360 372. doi: 10.1002/path.4523
29. Li J, Philip JL, Xu X, Theccanat T, Abdur Razzaque M, Akhter SA, β-Arrestins regulate human cardiac fibroblast transformation and collagen synthesis in adverse ventricular remodeling. J Mol Cell Cardiol 2014 76 73 83. doi: 10.1016/j.yjmcc.2014.08.006
30. Ng J, Villuendas R, Cokic I, Schliamser JE, Gordon D, Koduri H, Benefield B, Simon J, Murthy SN, Lomasney JW, Wasserstrom JA, Goldberger JJ, Aistrup GL, Arora R, Autonomic remodeling in the left atrium and pulmonary veins in heart failure: creation of a dynamic substrate for atrial fibrillation. Circ Arrhythm Electrophysiol 2011 4 388 396. doi: 10.1161/CIRCEP.110.959650
31. Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S, Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation 2002 105 2672 2678. doi: 10.1161/01.CIR.0000016826.62813.F5
32. Burstein B, Nattel S, Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008 51 802 809. doi: 10.1016/j.jacc.2007.09.064
33. Polyakova V, Miyagawa S, Szalay Z, Risteli J, Kostin S, Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 2008 12 189 208. doi: 10.1111/j.1582-4934.2008.00219.x
34. Pellman J, Lyon RC, Sheikh F, Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation. J Mol Cell Cardiol 2010 48 461 467. doi: 10.1016/j.yjmcc.2009.09.001
35. Corradi D, Callegari S, Maestri R, Heme oxygenase-1 expression in the left atrial myocardium of patients with chronic atrial fibrillation related to mitral valve disease: its regional relationship with structural remodeling. Hum Pathol 2008 39 1162 1171. doi: 10.1016/j.humpath.2007.12.007
36. Corradi D, Callegari S, Benussi S, Nascimbene S, Pastori P, Calvi S, Maestri R, Astorri E, Pappone C, Alfieri O, Regional left atrial interstitial remodeling in patients with chronic atrial fibrillation undergoing mitral-valve surgery. Virchows Arch 2004 445 498 505. doi: 10.1007/s00428-004-1040-2
37. Edgley AJ, Krum H, Kelly DJ, Targeting fibrosis for the treatment of heart failure: A role for transforming growth factor-β. Cardiovasc Ther 2012 30 e30 e40. doi: 10.1111/j.1755-5922.2010.00228.x
38. Cai H, Griendling KK, Harrison DG, The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003 24 471 478. doi: 10.1016/S0165-6147(03)00233-5
39. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D, NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005 97 900 907. doi: 10.1161/01.RES.0000187457.24338.3D
40. Zhao W, Zhao T, Chen Y, Ahokas RA, Sun Y, Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol Cell Biochem 2008 317 43 50. doi: 10.1007/s11010-008-9803-8
41. Yeh YH, Kuo CT, Chan TH, Chang GJ, Qi XY, Tsai F, Nattel S, Chen WJ, Transforming growth factor-β and oxidative stress mediate tachycardia-induced cellular remodelling in cultured atrial-derived myocytes. Cardiovasc Res 2011 91 62 70. doi: 10.1093/cvr/cvr041
42. Lee KW, Everett TH IV, Rahmutula D, Guerra JM, Wilson E, Ding C, Olgin JE, Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006 114 1703 1712. doi: 10.1161/CIRCULATIONAHA.106.624320
43. Cohn A, Lahn MM, Williams KE, Cleverly AL, Pitou C, Kadam SK, Farmen MW, Desaiah D, Raju R, Conkling P, Richards D, A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer. Int J Oncol 2014 45 2221 2231. doi: 10.3892/ijo.2014.2679
44. Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U, Lahn M, Huber PE, Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011 71 7155 7167. doi: 10.1158/0008-5472.CAN-11-1212
45. Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK, IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006 70 1234 1243. doi: 10.1038/sj.ki.5001775
46. Okada H, Takemura G, Kosai K, Li Y, Takahashi T, Esaki M, Yuge K, Miyata S, Maruyama R, Mikami A, Minatoguchi S, Fujiwara T, Fujiwara H, Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure. Circulation 2005 111 2430 2437. doi: 10.1161/01.CIR.0000165066.71481.8E
47. Zhang P, Su J, Mende U, Cross talk between cardiac myocytes and fibroblasts: from multiscale investigative approaches to mechanisms and functional consequences. Am J Physiol Heart Circ Physiol 2012 303 H1385 H1396. doi: 10.1152/ajpheart.01167.2011
48. Panse KD, Felkin LE, López-Olañeta MM, Gómez-Salinero J, Villalba M, Muñoz L, Nakamura K, Shimano M, Walsh K, Barton PJ, Rosenthal N, Lara-Pezzi E, Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes. J Cardiovasc Transl Res 2012 5 814 826. doi: 10.1007/s12265-012-9400-9
49. Tian Y, Morrisey EE, Importance of myocyte-nonmyocyte interactions in cardiac development and disease. Circ Res 2012 110 1023 1034. doi: 10.1161/CIRCRESAHA.111.243899
50. Ottaviano FG, Yee KO, Communication signals between cardiac fibroblasts and cardiac myocytes. J Cardiovasc Pharmacol 2011 57 513 521. doi: 10.1097/FJC.0b013e31821209ee
51. Cartledge JE, Kane C, Dias P, Tesfom M, Clarke L, Mckee B, Al Ayoubi S, Chester A, Yacoub MH, Camelliti P, Terracciano CM, Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. Cardiovasc Res 2015 105 260 270. doi: 10.1093/cvr/cvu264
52. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, Nattel S, Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 2000 101 2631 2638. doi: 10.1161/01.CIR.101.22.2631
53. Kaur K, Zarzoso M, Ponce-Balbuena D, Guerrero-Serna G, Hou L, Musa H, Jalife J, TGF-β1, released by myofibroblasts, differentially regulates transcription and function of sodium and potassium channels in adult rat ventricular myocytes. PLoS One 2013 8 e55391. doi: 10.1371/journal.pone.0055391
54. Ramos-Mondragón R, Vega AV, Avila G, Long-term modulation of Na+ and K+ channels by TGF-β1 in neonatal rat cardiac myocytes. Pflugers Arch 2011 461 235 247. doi: 10.1007/s00424-010-0912-3
55. Narayan SM, Franz MR, Clopton P, Pruvot EJ, Krummen DE, Repolarization alternans reveals vulnerability to human atrial fibrillation. Circulation 2011 123 2922 2930. doi: 10.1161/CIRCULATIONAHA.110.977827
56. Krummen DE, Bayer JD, Ho J, Ho G, Smetak MR, Clopton P, Trayanova NA, Narayan SM, Mechanisms of human atrial fibrillation initiation: clinical and computational studies of repolarization restitution and activation latency. Circ Arrhythm Electrophysiol 2012 5 1149 1159. doi: 10.1161/CIRCEP.111.969022
57. Franz MR, Jamal SM, Narayan SM, The role of action potential alternans in the initiation of atrial fibrillation in humans: A review and future directions. Europace 2012 14(suppl 5) v58 v64. doi: 10.1093/europace/eus273
58. Narayan SM, Kazi D, Krummen DE, Rappel WJ, Repolarization and activation restitution near human pulmonary veins and atrial fibrillation initiation: A mechanism for the initiation of atrial fibrillation by premature beats. J Am Coll Cardiol 2008 52 1222 1230. doi: 10.1016/j.jacc.2008.07.012
59. MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M, Denvir M, Bhagra S, Small S, Martin W, McMurray JJ, Petrie MC, Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: A randomised controlled trial. Heart 2011 97 740 747. doi: 10.1136/hrt.2010.207340
60. Wilton SB, Fundytus A, Ghali WA, Veenhuyzen GD, Quinn FR, Mitchell LB, Hill MD, Faris P, Exner DV, Meta-Analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patients with versus without left ventricular systolic dysfunction. Am J Cardiol 2010 106 1284 1291. doi: 10.1016/j.amjcard.2010.06.053
61. Estner HL, Hessling G, Ndrepepa G, Wu J, Reents T, Fichtner S, Schmitt C, Bary CV, Kolb C, Karch M, Zrenner B, Deisenhofer I, Electrogram-guided substrate ablation with or without pulmonary vein isolation in patients with persistent atrial fibrillation. Europace 2008 10 1281 1287. doi: 10.1093/europace/eun244
62. Soucek R, Thomas D, Kelemen K, Bikou O, Seyler C, Voss F, Becker R, Koenen M, Katus HA, Bauer A, Genetic suppression of atrial fibrillation using a dominant-negative ether-A-go-go-related gene mutant. Heart Rhythm 2012 9 265 272. doi: 10.1016/j.hrthm.2011.09.008
63. Trappe K, Thomas D, Bikou O, Kelemen K, Lugenbiel P, Voss F, Becker R, Katus HA, Bauer A, Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: A pre-clinical pilot study. Eur Heart J 2013 34 147 157. doi: 10.1093/eurheartj/ehr269
64. Corradi D, Callegari S, Manotti L, Persistent lone atrial fibrillation: clinicopathologic study of 19 cases. Heart Rhythm 2014 11 1250 1258. doi: 10.1016/j.hrthm.2014.02.008
65. McGann C, Akoum N, Patel A, Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI. Circ Arrhythm Electrophysiol 2014 7 23 30. doi: 10.1161/CIRCEP.113.000689
66. Ciaccio EJ, Biviano AB, Whang W, Gambhir A, Garan H, Different characteristics of complex fractionated atrial electrograms in acute paroxysmal versus long-standing persistent atrial fibrillation. Heart Rhythm 2010 7 1207 1215. doi: 10.1016/j.hrthm.2010.06.018
67. Ciaccio EJ, Biviano AB, Whang W, Vest JA, Gambhir A, Einstein AJ, Garan H, Differences in repeating patterns of complex fractionated left atrial electrograms in longstanding persistent atrial fibrillation as compared with paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol 2011 4 470 477. doi: 10.1161/CIRCEP.110.960153
68. Hayward RM, Upadhyay GA, Mela T, Ellinor PT, Barrett CD, Heist EK, Verma A, Choudhry NK, Singh JP, Pulmonary vein isolation with complex fractionated atrial electrogram ablation for paroxysmal and nonparoxysmal atrial fibrillation: A meta-Analysis. Heart Rhythm 2011 8 994 1000. doi: 10.1016/j.hrthm.2011.02.033
69. Narayan SM, Krummen DE, Clopton P, Shivkumar K, Miller JM, Direct or coincidental elimination of stable rotors or focal sources may explain successful atrial fibrillation ablation: on-treatment analysis of the CONFIRM trial (Conventional ablation for AF with or without focal impulse and rotor modulation). J Am Coll Cardiol 2013 62 138 147. doi: 10.1016/j.jacc.2013.03.021
70. Solheim E, Off MK, Hoff PI, Schuster P, Ohm OJ, Chen J, Characteristics and distribution of complex fractionated atrial electrograms in patients with paroxysmal and persistent atrial fibrillation. J Interv Card Electrophysiol 2010 28 87 93. doi: 10.1007/s10840-010-9479-3
71. Xi Q, Sahakian AV, Frohlich TG, Ng J, Swiryn S, Relationship between pattern of occurrence of atrial fibrillation and surface electrocardiographic fibrillatory wave characteristics. Heart Rhythm 2004 1 656 663. doi: 10.1016/j.hrthm.2004.09.010